Asia FX muted despite Fed cut bets; Japanese yen slides after PM Ishiba resigns
Arcutis Biotherapeutics (NASDAQ:ARQT) director Howard G. Welgus sold 10,000 shares of common stock on September 2, 2025, at prices ranging from $15.45 to $15.81, for a total of $156,383. The biotherapeutics company, currently valued at $1.95 billion, has seen its stock surge nearly 55% over the past year. According to InvestingPro analysis, the stock appears slightly undervalued at current levels.
On the same day, Welgus also exercised options to acquire 10,000 shares of Arcutis Biotherapeutics common stock at an exercise price of $1.6806. These options were fully vested and had an expiration date of March 13, 2029. InvestingPro data shows the company maintains strong financial health with a current ratio of 3.2, indicating solid liquidity. Get access to 10+ additional exclusive ProTips and comprehensive analysis with an InvestingPro subscription.
In other recent news, Arcutis Biotherapeutics reported its second-quarter earnings for 2025, exceeding both earnings per share (EPS) and revenue forecasts. The company achieved an EPS of -$0.13, outperforming the projected -$0.17, and reported revenue of $81.5 million, which surpassed expectations by 11.26%. Additionally, Arcutis has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration to expand the use of its ZORYVE cream for treating plaque psoriasis in children as young as 2 years old. If approved, this would mark ZORYVE as the first topical PDE4 inhibitor for this age group. Meanwhile, Palvella Therapeutics has appointed David W. Osborne as Chief Innovation Officer. Dr. Osborne, who co-founded Arcutis Biotherapeutics and has extensive experience in developing topical therapies, will bring his expertise to Palvella. These developments highlight ongoing advancements and leadership changes in the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.